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Abstract  
To say that tuberculosis (TB) has regained a strong foothold in the global human health and 
wellbeing scenario would be an understatement. Ranking alongside HIV/AIDS as the top 
reason for mortality due to a single infectious disease, the impact of TB extends far into 
socio-economic context worldwide. As global efforts led by experts and political bodies 
converge to mitigate the predicted outcome of growing antimicrobial resistance, the 
academic community of students, practitioners and researchers have mobilised to develop 
integrated, inter-disciplinary programmes to bring the plans of the former to fruition.  
Enabling this crucial requirement for unimpeded dissemination of scientific discovery was 
the TB Summit 2016, held in London, United Kingdom. This report critically discusses the 
recent breakthroughs made in diagnostics and treatment while bringing to light the major 
hurdles in the control of the disease as discussed in the course of the three-day 
international event. Conferences and symposia such as these are the breeding grounds for 
successful local and global collaborations and therefore must be supported to expand the 
understanding and outreach of basic sciences research.   
5 
 
Introduction 
For a disease that should largely be under control, tuberculosis (TB) still claims over 1.5 
million lives every year with children accounting for 140,000 of them.1 Amongst the multiple 
factors that contribute to the success of the disease are the recalcitrant nature of the causal 
pathogen Mycobacterium tuberculosis and the growing drug-resistance acquired by it 
through decades of treatment with a fixed regimen of drugs. Lengthy diagnostic procedures, 
incorrect diagnoses followed by inadequate prescription of treatment enable resistant 
strains to spread within and outside communities. This is further complicated as TB is largely 
associated with resource-poor countries that have high population densities where contact 
tracing programmes are compromised due to lack of infrastructure.2 However, the bleak 
environment has fuelled the need for innovative, rapid and accurate diagnostic tests based 
molecular techniques such as the GeneXpert® MTB/RIF that are being widely used all over 
the world.3 These technologies require further development to suit the need of the hour in 
poor areas with low infrastructural support. For effective control of the disease, advances in 
diagnosis must be mirrored by the advent of effective therapeutics to treat the infection.  
Antimicrobial drug discovery is often viewed as a high-risk/low-reward endeavour and this 
sector was ignored by the pharmaceutical companies and concurrently overlooked by public 
health policies alike. This has resulted in a critical shortage of novel drug entities in clinical 
trials. As extensively drug-resistant (XDR)-TB has now been detected in 105 countries, the 
US FDA has granted accelerated options for anti-TB drug development.1 After around half-
decade of no novel drugs for treatment, multi-drug resistant (MDR) TB patients finally have 
the option, albeit under strict regulations, of receiving bedaquiline or delamanid for 
treatment.4, 5  
The public cost of TB treatment in most cases ranges between US$ 100-500 increasing to 
US$ 10,000 in the case of MDR TB patients.1 The rise of antimicrobial resistance (AMR) has 
been predicted to cost the global economy between £2.1 trillion to over £100 trillion in the 
year 2050, based on the interventions taken and their effectiveness.6 This burden would be 
a direct outcome of the predicted annual loss of 10 million lives in their most productive 
years if AMR was to spread without control.  TB holds a major share of the burden caused 
due to AMR. Adding to this, the impact of TB in animal husbandry has severe implications as 
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there are no vaccines or practical, cost-effective means of treating infected animals. Parts of 
Wales in the United Kingdom have reported a staggering increase in the number of cattle 
slaughtered owing to bovine TB.7 These cullings have put an inadvertent strain on the 
animal farming industry and local governments.  
In today’s global world and economy, an amalgamation of efforts starting from the student 
at the bench needs to go through to the supply chain which eventually lands the finished 
diagnostic or therapeutic product used at the point-of care or by the patient’s bed. 
Scientists need to understand the ground realities and the difficulties faced by healthcare 
workers to come up with effective solutions and strategies. In a similar manner, physicians 
need to be informed of the latest advancements in basic sciences research to generate 
quicker feedback mechanisms that can highlight areas of pressing need for development. It 
is therefore essential to initiate lines of communication between these diverse set of 
individuals united by their efforts to control TB. 
The TB Summit 2016, the third such event organised by Euroscicon, was fittingly held at 
North Greenwich, London (UK) as it is one of the boroughs with the highest incidences of TB 
in London.8-10 The three day event was well attended with representatives from universities 
and government agencies from all over the world. The informative oral presentation and 
poster sessions were categorised for a systematic discussion on the different aspects of TB 
as is discussed in more detail in the following sections of the report.  
Tuberculosis: the disease, the pathogen and the host 
Studying the spread of tuberculosis 
TB, in its most common form is an air-borne disease that invades the lung tissues and 
resides in the macrophages and other phagocytic immune cells of the host. The host 
immune responses serve to sequester the organism in compartments known as 
granuloma.11 These granulomas mature further to form necrotic lesions which are finally 
broken down by mechanical shear and released into air by the act of coughing or talking by 
the infected persons.12 Though the airborne route for transmission is widely accepted, 
adequate investigation into the different stages of disease, namely: expulsion of bacteria, 
transmission via air, inhalation and infection of new host needs to be carried out.  
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The act of coughing is considered important for TB transmission as it is a common symptom 
of pulmonary TB. As M. tuberculosis is encased within the lung cavities in thick biofilms a lot 
of force is required to shed the bacilli into the airways and out. Coughing releases more 
droplets than other manoeuvres such as talking or singing as higher force is involved in the 
former act and is thus considered to be the major factor involved in the transmission 
mechanism.13, 14 Several studies studying cough patterns and household transmission have 
shown that patients cough more during the day than at night and that cough frequency is an 
important predictor of transmission.15, 16 As noted by Richard Turner (NHS Foundation Trust, 
UK), the act of coughing in the context of infectiousness of TB has not been looked into. The 
cause of cough in a TB patient; its necessity for the transmission of TB, correlation with 
infective/non-infective strains of the pathogen and characteristics of the optimum cough 
droplet for disease transmission are yet to be completely understood. Factors such as 
airway anatomy and the quantity, composition and viscosity of sputum have been 
overlooked and methodologies to investigate them need to be developed. 
Investigating transmission patterns of TB can help develop effective intervention strategies 
to control the disease. Exhaustive transmission tracing studies should be able to detect or 
rule out transmission between cases, track the successive acquisition of single nucleotide 
polymorphisms (SNPs) along the chain of transmission and differentiate between primary 
and acquired resistance phenotypes while accounting for host diversity. However, TB 
infections are notorious for their heterogeneity within the same host as the lengthy 
infection period allows for microevolution of the bacilli within the duration of one infection 
cycle.17 On the other hand, the pathogen has a slow-replication rate and a proclivity towards 
low genetic diversity. Thus the bacilli may either show no genetic diversity or the presence 
of multiple SNPs between contacts making it extremely difficult to trace transmission using 
their gene sequence alone. Caroline Colijn (Imperial College London, UK) suggests 
combining dated phylogenetic trees with statistical modelling to reveal the likelihood of a 
transmission tree using Markov chain Monte Carlo simulation/Bayesian inference 
methods.18  However, using statistical methods to infer the transmission of the tubercle 
bacilli requires computationally intensive inference methods which suffer from the 
limitations of the available data and assumptions made to build the models as indicated by 
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Jarno Lintusaari (Aalto University, Finland).19 The complexity of the process makes it difficult 
to draw reliable inferences from statistical models of transmission dynamics.  
Albert Nienhaus (University Medical Center, Germany), James Seddon (Imperial College 
London, UK) and Robert Wilkinson (University of Cape Town, SA) discussed the hurdles in 
the control of transmission amongst different sets of high-risk individuals- healthcare 
workers, children and HIV patients.  
Talking about occupational acquirement of disease, Prof Nienhaus stated that TB is one of 
the most infectious disease affecting healthcare workers (HCW) in Germany.20 The situation 
is worse in countries such as Portugal and France where occurrence rates are decidedly 
higher at 33% and 19% compared to Germany’s 10%.21, 22 
HCW, especially physicians and nurses are at a higher risk of acquiring active and latent TB 
infection (LTBI) because of prolonged and frequent contact with infected patients. In 
contrast, this group has lower transmission rates to contacts than other groups of infected 
individuals as a result of frequent health checks.23 After close scrutiny of the screening data 
of 32 practitioners, Prof Nienhaus recommended an annual screen of HCW at high-risk due 
to contact with highly-infectious patients. However, screening guidelines issued by the 
public health systems of different countries suggest a varied combination of X-ray, 
tuberculin skin test (TST) and interferon-γ release assays (IGRA) with no consensus on the 
best strategy.24, 25 He suggested that in circumstances when IGRA is positive and X-ray 
negative, LTBI can be confirmed and followed by prophylactic measures if the risk of 
avoiding treatment is deemed higher than the risk posed by administering it. Encouragingly 
the detection of LTBI in HCW has been increasing over the years as diagnostic technologies 
improve and it is expected that investigations into the risk-reward dynamics of treatment 
will allow for the development of a uniform global solution. 
Another group at high-risk of acquiring the disease owing mainly due to their association 
with infected adults are children. In spite of one million cases of TB being reported in 
children, very little is being done to understand the pathogenesis and treatment options 
available for them. Dr Seddon has been working towards improving our understanding of 
treatment and prevention option of MDR-TB in children.26 TB in children and infants is 
difficult to diagnose as sputum collection is difficult. Complicating matters further, the 
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disease manifests in multiple forms including infection of the intra- or extrathoracic lymph 
nodes.27  Hence treatment must be tailored according to child’s needs and health status.  
Though studies point out that almost all children who are diagnosed, complete their therapy 
and have very good outcomes; regimens for MDR-TB in children require an overhaul as the 
pharmacokinetics and toxicity of drugs in children are significantly different from that 
observed in adults.28, 29 The regimen for drug-susceptible TB in children is the standard six 
month combination therapy where rifampicin, isoniazid, and pyrazinamide are administered 
for the initial 2 months followed by 4 months of rifampicin and isoniazid.30 In children 
suffering from HIV and TB, additional ethambutol is advised in the first two months. Future 
trials to assess TB prevention strategies include TB-CHAMP to evaluate levofloxacin in 
children under 5 and ACTG A5300 to evaluate levofloxacin and isoniazid in adults and 
children amongst several others.26, 31 As new and repurposed drugs enter the therapeutic 
regimens, evaluation of their pharmacokinetic properties in children remains essential.  
Prof Wilkinson and his team are looking at the association between TB and HIV in 
Khayelitsha, South Africa. Khayelitsha is an impoverished township where the prevalence of 
TB is one of the highest seen around the world. Antenatal HIV prevalence is reported to be 
25% of the total population wherein almost 40% have the risk of developing active TB.32 
Furthermore, 76% of TB cases are also HIV positive.32 The team carried out a randomised 
controlled trial of antiretroviral therapy (ART) alone and isoniazid preventive therapy (IPT) 
combined with ART (cART) for prevention of HIV-associated TB. The results indicated that 
isoniazid added to the anti-viral therapy reduces the risk of TB by 35% as observed after a 
year of IPT therapy.33 He also estimated that individuals infected with HIV have around 
thirty times the risk of acquiring active TB due to immunosuppression and in very high 
incidence environments, a reinfection is more common than an endogenous reactivation of 
disease.34  
 
Mycobacterium tuberculosis: a closer look 
The genus Mycobacterium has undergone several speciation and genetic decay events to 
give rise to a variety of non-pathogenic and pathogenic species with varying host-
specificities. Unlike other bacteria, mycobacterial species are not involved in horizontal gene 
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transfer hence evolution is gradual, driven by small genetic changes regulated by natural 
selection or associated with human evolution and their paleomigration. The course of these 
genetic drifts has caused M. tuberculosis to become an obligate pathogen with the host-
specificity restricted primarily to humans.35 Frédéric Veyrier (INRS-Institut Armand-Frappier, 
Canada) has been using gene sequencing technologies to reveal the factors that make M. 
tuberculosis human-specific. Two approaches were tried: (a) the ‘aimless’ method which 
included next-generation sequencing (NGS) and mycobacterial homologue investigation tool 
(mycoHIT) and (b) the ‘focussed’ approach which narrowed in on the loci of interest. Their 
main interest was to investigate the genetic mutations that are selected during the process 
of evolution towards becoming an obligate pathogen.35  
Whole-genome sequencing can help differentiate between fast and slow growing 
mycobacteria. These studies revealed M. kansasii to be a potential candidate to model an 
ancestral image of M. tuberculosis being an environmental species that can cause TB-like 
disease that cannot be transmitted.36  The genetic analyses revealed an explosion of toxin-
antitoxin modules in M. tuberculosis after speciation, mostly by gene duplication. Another 
specific adaptation is anaerobic respiration.37, 38 Ancestral genetic events could explain the 
sequential evolution of the pathogen and the ongoing functional characterisation of these 
events could be reconstructed in M. kansasii or M. marinum.  
Moving on from the clues in the genetic code to the message–relay system, Eric Galburt 
(Washington University School of Medicine, USA) discussed the kinetics and energetics of 
transcription initiation in mycobacteria. Though a fundamental biological process that is 
common to, and conserved in bacteria; transcription rates vary largely between E. coli and 
mycobacterial species owing to the differences in stability of the intermediate complexes 
formed in this process. Hence it is important to study the central processes in the pathogen 
itself rather than inheriting information from other model organisms. The essential 
transcription initiation factors CarD (Rv3583c) and RbpA (Rv2050) play important roles in 
the biology of M. tuberculosis.39-42 Initiation requires the formation of RNA polymerase 
(RNAP) holoenzyme with the bound sigma factors. A series of kinetic steps bring about the 
formation of a closed complex leading to the open complex with the transcription bubble. 
The initiation factors are positioned near the upstream edge of the transcription bubble.43, 44 
Techniques such as fluorescent labelling were used to study the open complex using M. 
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bovis RNAP which is known to form open complexes that are more unstable as compared to 
E.coli RNAP.  It was found that the initiation factors act independently and cooperatively to 
regulate transcription and the only in the presence of both factors does the transcription 
kinetics in mycobacteria appear to be similar to that observed in E. coli.45, 46 As both factors 
are known to play important roles in pathogenesis, global rRNA/gene expression levels and 
resistance to stress and antibiotics, they would serve as good targets for drug design. 
A major challenge to the development of effective drugs and treatment regimens against M. 
tuberculosis is the heterogeneity of the infecting population of bacilli which include actively 
replicating and dormant cells known as persisters. Persister cells are quiescent, highly 
tolerant towards antibiotics and other external stresses and under favourable conditions 
can revert to actively dividing states.47 Detection of these cells is near impossible as 
conventional microbiological techniques of culture cannot identify them. These cells can be 
generated in vitro in prolonged stationary phase culture or gradual acidification of culture 
medium. They can then be reverted to their actively replicating physiology by exposure to 
resuscitation promoting factors (Rpfs) and are also known as Rpf-dependent cells.48 
Rpfs are secreted or cell-wall bound enzymes produced by actively dividing mycobacteria. 
They are structurally and functionally similar to lysozymes and are essential for resuscitating 
dormant cells.49 There are five Rpfs in M. tuberculosis and they have been found to be 
important for persistence and reactivation of infection in mice. RpfA, B and E are secreted 
and found in culture filtrates whereas RpfC is cell-bound.50 RpfD is upregulated during 
infection. Once revived, Rpf-dependent cells lose this characteristic dependency during in 
vitro passages.  
Rpf-dependent mycobacteria are very importantly in the clinical aspect.48 These cells are 
highly abundant in sputum and extra pulmonary TB samples with their relative proportions 
varying from 0 to 99.99% of the total M. tuberuclosis population. Jaishree Garhyan 
(Jawaharlal Nehru University, India) reported bone marrow to be a niche for persisters as 
the mesenchymal stem cells survive for an extended period of time and reside in immune 
suppressed environments.51, 52 Additionally, stem cells have active drug efflux cells providing 
a second wall of defence for the pathogen. Their work indicates that M. tuberculosis hijack 
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mesenchymal stem cells, reprogramme them through hypoxia inducible factor (Hif-1) and 
targeting this pathway could potentiate standard treatment regimens.  
Rpf-dependent cells are inherently more resistant to several drugs such as rifampicin, 
isoniazid and streptomycin.53  As it is more difficult to get rid of Rpf-dependent 
mycobacteria they are found to be enriched in treated TB patients. As persisters are often a 
cause of treatment failure and post-treatment relapses it is essential that evaluation of TB 
treatment regimens accounts for elimination/induction of this group of cells.54 Yanmin Hu 
(St George's University of London, UK) believes the invisible persisters represent a promising 
therapeutic target and shorter chemotherapy such as the one trialled with fluoroquinolones 
can only be successful if they are effective in decimating this subset of the pathogenic 
population. Under in vitro conditions, her group observed that high doses of rifampicin are 
required to kill stationary cultures of M. tuberculosis.47 This is mainly owing to the Rpf-
dependent bacilli which are highly tolerant to the drug and appear to decrease with 
increasing concentrations of rifampicin but cannot be completely eradicated.47  When they 
incubated infected mouse lung tissues (2 week infection time) with culture filtrate 
containing Rpfs, the persister cells could be revived even after the mice were administered 
with high-dose rifampicin treatment. They used the Cornell model to study the efficacy and 
relapse rate of different drug treatment regimens, wherein the infection was allowed to 
establish for 3 weeks and then treated with drug combinations for 14 weeks. On the end of 
treatment period the mice were given hydrocortisone to suppress the immune system to 
study relapse rate. As noted with the earlier model, dose-dependent killing of bacteria was 
observed. It was also noted that higher doses of rifampicin can enable shortening of 
treatment time however, a small subset of Rpf-dependent bacilli still persist in the host 
tissues.  
Galina Mukamolova (University of Leicester, UK) introduced the concept of drug-induced 
Rpf-dependency in M. tuberculosis. Treatment with rifampicin, isoniazid and ethambutol 
was shown to induce Rpf-dependency, whereas no such effect was observed in the case of 
treatment with streptomycin and amikacin.53 Thereby it is critical that drugs be tested for 
their propensity to induce Rpf-dependency. Towards this end, Mukamolova and co-workers 
strived to design a simple assay to determine potential of drugs to induce Rpf-dependency. 
Rpf-dependent mycobacteria can be generated during infection in mice. However, these 
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models are difficult to process in a high-throughput setting. To adapt this to in vitro settings, 
the Mukamolova group synthesised novel nitric oxide donors which could induce persister 
phenotype in M. bovis cells.  These in vitro systems can thus be used for validation of novel 
drugs and the search for Rpf-dependency biomarkers alike.  
Another model for persistence, using the toxin-antitoxin (TA) modules found littered in the 
M. tuberculosis genome, was discussed by Shaleen Korch (Midwestern University, USA). Out 
of the 88 putative TA modules identified, around 30 have been assigned functions.55 These 
are typically two-gene operons, wherein one encodes a toxic protein and the other encodes 
an antitoxin that binds to and inhibits the toxin.56 Regulation of these modules is controlled 
mostly through auto-repression of transcription of the operon by the antitoxin. However, 
upon exposure to stresses encountered during infection a certain subset of these modules 
are activated. Given that in E. coli, these systems are known to be involved in generating 
persisters, their role in controlling M. tuberculosis division rates during infection needs 
further investigation.57 Korch chose to focus on the RelBE system which inhibits translation 
through mRNA cleavage.58, 59 By generating strains that overexpress the toxins followed by 
antitoxin rescue they demonstrated a persistence phenotype wherein only 20% of total 
translation was observed.60 This model will enable further investigation into the stages of 
persistence namely, entrance, maintenance and exit.  
Host responses to M. tuberculosis 
Macrophages are the sentinel of the innate immune system. Once M. tuberculosis gains 
entry into the airways of a suitable host it encounters phagocytic cells and invades alveolar 
macrophages and monocytes preferentially. Once infected, these macrophages release a 
host of cytokines that recruit several immunologically active cells such as the T-cells which 
release interferon-γ (IFNγ) which in combination with tumour necrosis factor-α (TNFα) 
activate macrophages to eliminate the pathogen.61 Marcin Wlodarczyk (University of Lodz, 
Poland) is interested in the profile of mycobacterial antigen driven cytokine responses and 
the expression of signal transduction receptors in TB. Two hundred and eighteen BCG 
vaccinated, HIV-/TB+ patients were chosen for the study. The main objectives of the 
research was to assess the production of IFNγ, TNFα, interleukins and the cell-surface 
expression of receptors such as TLR2, LFA-1, CD14 as well as the soluble counterpart of 
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CD14 between the patients and healthy volunteers. They report to observe quantitative 
rather than qualitative changes in the expression levels of the cytokines studied when 
serum from infected individuals were challenged with mycobacterial antigens. TB patients 
were also found to have a significantly higher frequency of monocytes with CD14, TLR2 and 
LFA-1 receptors.62 
Another Toll-like receptor family member, RP105 (CD180) is under investigation by Antje 
Blumenthal’s group (The University of Queensland Diamantina Institute, Australia). RP-105 
mainly expressed by macrophages and monocytes. It has a short cytoplasmic tail and it has 
been suggested that it cannot signal directly without a signalling partner. CD180 mRNA 
expression levels are higher in whole-blood of cured TB patient versus those who relapse.63 
It was also shown that RP105 deficient mice are more susceptible to TB and RP105 deficient 
macrophages produced significantly reduced amounts of inflammatory cytokines than their 
wild-type counterparts.64 However, neither mRNA nor protein expression of inflammatory 
cytokines such as TNF were affected in RP105 deficient mutants macrophages.64 Through 
their work the Blumenthal group have demonstrated the RP105-mediated macrophage 
activation to be distinct from classical Toll-like receptor (TLR) signalling where RP105 directs 
cytokine trafficking.65, 66 This novel innate immune signalling pathway involves RP105, BTK 
and the p110δ subunit of phosphoinositide 3-kinase.  
Another family of small proteins, the interferon induced transmembrane (IFITM) proteins, 
and their role in restricting M. tuberculosis infection was introduced by Shahin Ranjbar 
(Harvard Medical School, USA).67 TLR2 and 4 and MyD88-dependent signalling pathways 
engage in the induction of the IFITM proteins 1, 2 and 3. Their work revealed that 
expression levels of the IFITM proteins directly correlated to the growth rates of M. 
tuberculosis in THP-1cells. IFITM3 was seen to co-localise with mycobacterial cells in alveolar 
epithelial cells and overexpression of the protein enhanced endosomal acidification thereby 
limiting the infection.67 
Bringing the discussion from receptors to signalling molecules, Maria Regina D'Imperio 
Lima (Universidade de São Paulo, Brazil) spoke about the role of purines, especially 
extracellular ATP (eATP) in the immune response to severe TB. Hypervirulent mycobacterial 
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strains show varying degrees of pathogenicity. The disease severity is often associated with 
suppression of effector cytokine production.  
eATP and its breakdown product, adenosine are known to act as a chemotactic signals 
leading to enhanced migration of neutrophils and macrophages to the site of 
inflammation.68, 69 eATP is known to activate several receptors that in turn induces cell 
death by necrosis, formation of ion channels or pyroptosis.70 These mechanisms enable 
release of bacteria from the phagocytic cells and it has been observed that TB caused by 
hypervirulent mycobacteria is attenuated in mice that lack the P2X7 receptor and there is a 
decrease in disease dissemination.71 The wild-type cells with active P2X7 die of necrosis 
which contributes to release of the hypervirulent mycobacteria.71 Histological analyses also 
revealed less inflammation-induced damage in the knockout mice thus demonstrating that 
P2X7 signalling contributes to the pathology in a severe infection model. The group also 
noted that specific CD4 cells in the pulmonary parenchyma of mice infected with virulent 
mycobacterial strains are suppressed.  
Annemarie H. Meijer (Leiden University, Netherlands) uses 1-day old zebrafish embryos 
infected with M. marinum, a close relative of M. tuberculosis to study the mechanisms of 
host defence in the early stages of infection. The advantage of studying these organisms is 
that they are optically transparent and cell aggregates and their dispersal can be easily 
followed. The young embryos do not have adaptive immunity and the earliest immune cells 
are macrophages and neutrophils. Within minutes of infection the bacteria are 
phagocytosed. The infected cells recruit new macrophages and consequently 
granulomatous aggregates are formed. The granuloma wards the pathogen from further 
immunological intervention and thereby offers its great advantage. 72 A steady secretion of 
early secretory antigen-6 (ESAT-6) by the pathogen ensures maintenance and growth of the 
granulomas. This agrees with the finding that ESAT-6 deficient mutants can only sustain 
small granulomas. Prof Meijer and her group focus on the chemokine network that 
facilitates the migration of the macrophages to form the granuloma.  
In zebrafish with mutated CXCR3 receptor, random motility of macrophages is reduced.73 
This motility defect correlates with reduction in number and size of granuloma translating to 
the decrease in total burden of infection. Inhibition of the CXCR3 receptor showed reduction 
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in granuloma formation and previous studies showed CXCR3 deficient mice to exhibit an 
increased resistance to infection.73 Hence targeting granuloma formation through the use of 
immunomodulatory drugs could help develop host-directed strategies that may work 
synergistically with chemotherapy and lower the risk of new resistance arising.  
Using zebrafish as a preclinical model they tried several methods to (a) inhibit granuloma 
expansion (b) reverse the inhibition of phago-lysosome fusion and (c) stimulate anti-
mycobacterial autophagy and autophagic efflux.74 Autophagy is an immunological defence 
system and numerous in vitro studies show that inhibition of autophagy promotes the 
growth of M. tuberculosis within host tissues.  
DNA damage related autophagy modulator1 (DRAM1) is upregulated during M. marinum 
infection dependent on the TLF/MyD88 pathogen recognition pathway.75 On overexpressing 
dram1 the fish larvae develop lower infection levels and smaller granuloma.  
Early diagnostics: the key to tackling TB?   
Out of the 9.6 million estimated cases worldwide in 2014 only 6 million were reported 
through national surveillance centres. Most of the 3 million undiagnosed cases are believed 
to be from regions where health services are weak. This is mainly owing to under-reporting 
and under-diagnosis. Under-reporting occurs when diagnosis and treatment are done in the 
private sector which is dis-associated from nationalised schemes. Secondly, paediatric 
services are often poorly-linked to the national TB services and children often go 
undiagnosed as detection of TB in these cases is especially difficult. Poor access to health 
care in low-income countries is the primary cause for under-diagnosis and many patients 
are lost to follow-up.  Most health centres carry out passive case finding whereas Luis E. 
Cuevas (Liverpool School of Tropical Medicine, UK) believes a more active approach 
incorporating outreach services could improve the situation. He compared two case studies 
of active case finding; one carried out in Ethiopia which has an active health extension 
programme and the other in Nigeria, which discontinued its health extension programme 
several decades ago. The study was carried out in the slums around Abuja in Nigeria. With 
the help of retired health extension workers (HEWs) and using resources such as the polio 
eradication census data, house-to-house visits were made to collect two sputum samples 40 
minutes apart. The results were notified at the individual’s home or through a phone call. 
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The case detection rate was doubled after the effort with increased diagnoses for women 
and the older population.76  
Ethiopia has a well organised health extension programme. In the study, the HEWs were 
provided basic health packages that were delivered on their house visits every 14 days. The 
main aim of the exercise was to improve TB case findings and treatment outcome. The 
HEWs were trained on case identification, collection of sputum and preparation of smears 
which were then dropped at the local laboratories. Once results confirmed TB infection the 
supervisor initiated treatment at home and domestic contacts would be screened.  There 
was at least a two-fold increase in detection from the previous year thereby clearly 
demonstrating improvements in TB case findings using the active case-finding approach.77, 78 
Andrew Curtis (Kent State University, USA) also supported this approach, he discussed the 
use of spatial video-camera footage and geo-narratives to enable active-contact tracing of 
the homeless and drug-user population who are at high-risk of acquiring the disease in 
developed countries. 
Sputum smear microscopy remains the mainstay of classical diagnostic tests used in low and 
middle-income countries with high-TB burden.79 This method is easy to perform, cheap and 
rapid but its use is limited due to poor sensitivity and specificity especially in paediatric 
cases, HIV patients and patients with low sputum bacterial loads.80 Liquid and solid culture 
techniques can take up to 3 weeks to obtain results at which point patient tracing may 
become difficult resulting in TB-infected individuals receiving no treatment and 
disseminating the disease within their communities and households precipitating the 
situation further. 
In an effort to develop a non-invasive, diagnostic strategy for TB using breath samples, Thu-
Hoa Tran-Thi (Centre National de la Recherche Scientifique, France) discussed the potential 
of volatile metabolites of M. tuberculosis as biomarkers for the disease.81, 82 Nicotinic acid 
(NA), methyl phenylacetate (MPA), methyl p-anisate (p-MA), methyl nicotinate (MN) and o-
phenylanisole are five volatile compounds that were identified from M. tuberculosis cultures 
grown in vitro.82 NA can be detected in breath of active TB patients although present in low 
amounts. It was also found to be a promising indicator of M. tuberculosis strains resistant to 
pyrazinamide. Dr Tran-Thi and group investigated a method to detect nicotinic acid (NA) in 
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complex solutions with different metabolites and also biological media. Luminescence 
techniques to detect NA using terbium III (Tb3+) as a probe owing to its property to 
luminesce on energy transfer from NA to the Tb3+ ion were developed.83 Potential 
interference by other metabolites such as MPA, p-MA and MN that have similar excitation 
wavelengths as NA in samples was identified as a challenge. Breath condensate was 
identified as the best sample as there is less interference compared to saliva and urine 
samples. The cost of this diagnostic process is estimated to be lesser than the World Health 
Organisation (WHO)-approved molecular diagnostic test, the GeneXpert® MTB/RIF, making 
its development a priority for subsequent use in developing countries. 
Blood biomarkers can also be exploited for use in diagnostic tests in detecting TB in endemic 
areas. As a whole host of antibodies specific to the various antigenic epitopes found in M. 
tuberculosis are generated in TB patients, single antibody profile-based detection methods 
are likely to fail. Imran Khan (University of California, USA) has looked into the use of a 
multiplex sero-detection panel for TB diagnosis.84 This test uses a panel of 28 M. 
tuberculosis antigen-coated microbeads which enables the universal identification of 
antibody profiles in patients by a single test. Using the same method, Dr Khan examined ten 
plasma cytokine/chemokine/growth-factor and eight antibodies against eight M. 
tuberculosis antigens biomarkers that are elevated in TB patients. Interestingly, they found 
the antibody profile levels among TB patients are gender biased and linked to treatment 
success.85 Immunobiomarkers in TB are valuable to understand host responses against the 
pathogen and this area could be further explored for development of TB diagnostics and 
treatment.  
Genomics, proteomics and transcriptomics are approaches that have been extensively 
utilised to characterise M. tuberculosis. Recently, metabolomics, a newer approach, has 
been complemented into the “omics” revolution to provide a more complete insight into 
the pathogen’s complex internal systems.86, 87 Metabolomics investigates all intra- and 
extra-cellular metabolites (small molecule intermediates and product) in a biological sample 
using highly specialized analytical techniques to create a metabolic profile and measures any 
dynamic responses to stimuli or genetic modifications.88-90 Du Toit Loots (North-West 
University, SA) is interested in characterizing M. tuberculosis using metabolomics and 
identifying its characteristic metabolite signatures. This approach can identify between the 
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different species of mycobacteria using specific metabolite markers, although the species 
are known to have minor genetic variations, illustrating the sensitivity of this approach.86 
Prof Loots conveyed his optimism of the possibility of using metabolite markers to build 
diagnostic models based on systematic approaches in metabolomics research.91-93 It could 
also assist in finding the association between TB and its symptoms; for example, increase 
epinephrine levels can predict weight loss and insomnia in patients. In the future, this 
approach could also be used to diagnose drug resistant TB and for prognosis.94 
Nucleic acid amplification tests (NAATs) are molecular diagnostic approaches that were 
developed to improve the sensitivity and specificity in diagnosing TB, and most importantly, 
to detect MDR-TB infections. The GeneXpert® MTB/RIF Ultra was introduced to this year’s 
TB Summit, highlighting the significant improvements on its earlier version. Elisa Tagliani 
(IRCCS San Raffaele Scientific Institute, Italy) promoted the new molecular diagnostics tool 
and hailed it to be transformational for TB detection/elimination efforts. The latest format 
uses bigger cartridges and extra probes detecting four new rpoB mutations, IS6110 and 
IS1081 from M. tuberculosis to enable detection of 30 different rifampicin-resistant M. 
tuberculosis rpoB mutations. With these advancements they hope to enhance the sensitivity 
of the assay close to liquid culture. 95 
Eric R. Houpt (University of Virginia, USA) spoke about the TaqMan array card (TAC). It is a 
genotypic method to detect pathogen mutation which provides two layers of accurate 
detection of mutations via sequence-specific probes and high-resolution melt analyses 
(HRM). It can detect mutations in genes that are indicated in resistance, such as rpoB, inhA, 
embB, gyrA to name a few.96 The method is easy to perform, reproducible and has good 
sensitivity and specificity. It has the potential to improve MDR-TB and XDR-TB detection 
hence improving the appropriateness and efficacy of TB treatment. 
Many of the commercially available NAAT formats are inaccessible in resource-poor centres 
due to the high costs related to instrumentation and consumables. PURE-TB-LAMP, a TB 
NAAT test, claims to be simple, fast, robust, sensitive (compared to smear microscopy) and 
affordable (compared to other NAAT platforms). Yasuyoshi Mori (Eiken Chemical Co., Ltd., 
Japan) spoke about this screening test kit that uses loop-mediated isothermal amplification 
(LAMP) that removes the needs for costly thermocycler or detection systems.97 The kit 
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consists of Loopamp™ PURE DNA Extraction Kit and Loompamp™ MTBC detection kit. Three 
main technical aspects of the test are (a) amplification of DNA with LAMP, (b) ultra-rapid 
extraction (PURE) of DNA that can remove inhibitors of the test without significant loss of 
genetic material and (c) straightforward visual detection of the result using fluorescence 
under ultra-violet light.98, 99 The Loopamp™ LF-160 machine does not need maintenance and 
calibration which makes the overall process simple and easy to pick up; dismissing the need 
for extensively trained personnel. The sensitivity of TB LAMP is 100 times higher than 
sputum smear microscopy.100 Currently, the screening test has been approved for use in 
Japan, China, South Korea and Thailand. Analyses of its clinical performance have been 
submitted to WHO for usage approval.  
Mediastinal TB is a form of extrapulmonary TB that is often seen in paediatric, HIV-infected 
patients and adult immigrants in developed countries. The number of reported cases of 
extra pulmonary TB in the UK has increased slightly in the past decade, a trend that is 
worrying.101 Diagnosis of mediastinal tuberculous lymphadenitis is challenging due to its 
nonspecific clinical presentation, normal chest X-ray examination result and low-yield 
sputum culture. 102, 103 These vague presentations require to be differentiated with other 
similar presenting diseases such as lymphoma, carcinoma and sarcoidosis.102 Onn Min Kon 
(Imperial College London, UK) emphasized that mediastinal TB should not be overlooked 
especially when normal chest X-ray is presented in patients with suspected isolated 
mediastinal lymphadenitis. A follow up thoracic PET/CT scan is compulsory to confirm a 
positive lymphadenopathy.104 Sampling of mediastinal lymph node tissue is obligatory to 
identify aetiology of the disease, previously mostly done using techniques such as cervical 
mediastinoscopy. However, this invasive technique is associated with significant morbidity 
and mortality hence endoscopic ultrasound-guided transbronchial needle aspiration (EBUS-
TBNA), commonly used in diagnosing lung cancer, is recommended as a minimally invasive 
alternative for mediastinal TB diagnosis.105-107 Prof Kon informed that this widely used 
microbiological diagnostic technique combined with  GeneXpert® MTB/RIF could enhance 
the sensitivity and specificity of mediastinal TB diagnosis, quicken the suspected cases’ 
assessment and enable rapid detection of resistant M. tuberculosis strains.108 
M. bovis is a member of the MTB complex and is promiscuous in host specificity. It can 
infect alpacas, llamas, dogs and cats that can then transmit to the animal owners. The UK 
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has not been able to contain the disease despite several radical measures being carried out 
to control the natural reservoir populations. Three months are required to diagnose M. 
bovis infection and it costs $140 per sample. Differentiation between M. bovis and M. 
tuberculosis infections are necessary as the former is inherently resistant to pyrazinamide.  
Traditional approaches to generate serological response tests either use non-pathogenic 
BCG strains or heat-killed/chemically-inactivated pathogens. These harsh conditions damage 
the important cell surface conformational epitopes which are not represented or 
maintained during detection. The novel approach tried by Linda Stewart (University of 
Belfast, UK) was to use gamma-irradiated pathogenic strains to develop M. bovis specific 
binders.109 The whole-cell or ethanol extracted surface antigens were used and both 
polyclonal as well as monoclonal antibodies were raised using phage display technology.  
The outcome of this was an array of binders that were characterised by ELISA and 
immunofluorescent staining. The main aim of their efforts was to develop a diagnostic assay 
that would use the binders for disease detection that could differentiate between M. bovis 
and M. tuberculosis infections unlike the commercially available kits in the market at 
present.  
Gustavo Moreira (Technische Universität Braunschweig, Germany), discussed the use of 
phage display for biomarker identification and generation of human antibodies for 
diagnostics and therapy. Antibody phage display involves an in vitro process, which does not 
involve the immune system. The process begins with insertion of the antibody genes into 
phage genome, which is then expressed as a fusion protein displayed on the outer surface 
of the phage. The next stage is called panning, where the antigen is interrogated with the 
library of antibodies that has been created. Identification of positively binding antibodies is 
performed by ELISA, immunoblot or flow cytometry.110  
M. tuberculosis secretes a protein called Antigen 85 (Ag85). Antibody genes from a naïve 
library were selected and were cloned into yeast display systems. This combination of phage 
and yeast display was used to produce antibodies against Ag85. Clones were screened for 
the highest antigen binding revealing 7 antibody pairs that can detect Ag85 at nanomolar 
concentrations, however none of the clones were strictly specific for one of the antigen 85 
subunits of the complex.111 Another study used 5 human antibodies against Ag85B from the 
22 
 
naive libraries, where three of them bounded specifically to the 85B proteins as tested by 
ELISA.112  
Monitoring host response to TB treatment can identify the efficacy of treatment and predict 
the likelihood of relapse. The current method to validate treatment success is through 
bacteriological culture conversion at 2 months from the onset of therapy. Bacterial 
transcriptomics offers a new avenue to study elimination of the pathogen from the patient. 
Dimitrios Evangelopoulos discussed molecular methods to detect the decline of bacterial 
load during treatment as a biomarker of infection progression. The method utilising 
detection of mycobacterial RNA has been developed from using an artificial matrix 
resembling sputum samples and applied to a clinical case concerning a 12 year old 
patient.113 In this case, staining methods detected the presence of acid-fast bacilli however 
liquid culture assays could not detect any live bacilli. On using the molecular bacterial load 
(MBL) assay, the patient was shown to have a high bacterial load and the treatment regimen 
was modified to include moxifloxacin. After a year of treatment, both MBL and staining 
assays did not detect any bacilli and the patient was confirmed as cured.  
A pilot study with mice established that this assay can also be used with tissues from 
animals.  MBL and colony forming unit (CFU) assays on the tissues of mice undergoing 
different treatments revealed that both the assays agreed with each other, with the former 
consistently detecting higher numbers of cells probably as a result of detecting the non 
culturable cell population.113 Therefore, the MBL assays can serve as a rapid and sensitive 
diagnostic and treatment monitoring tool, offer insight on drug efficacy and may be used in 
drug discovery. 
Drug Discovery: moving past the roadblocks 
The search for novel therapeutic targets 
Since the landmark announcement of the complete genome sequence of M. tuberculosis, 
there has been a focussed drive to identify important genes and visualise their protein 
products enabling target-based drug design projects to take-off. Tom Blundell (University of 
Cambridge, UK) is interested in exploring the biological space-going from genome to 
proteome. The traditional techniques of wet-lab research to understand the proteome of 
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the pathogen need to be underpinned by systems biology approaches. To this end Prof 
Blundell’s group has been working on Chopin, which inherits the information of the known 
structures for around 400 proteins and uses it to predict models for the remaining 3,500 
protein structures.114 Based on the information in publicly available databases; interactions, 
ligands and the oligomeric states of many of the proteins can be deciphered. This 
information can then be fed into structure-guided, fragment-based approaches in drug 
discovery. The rationale of this strategy is to use small molecules with promiscuous binding 
affinities to interrogate the substructures present with the protein targets using standard 
biophysical ligand binding assays. The hits are then optimised to yield a molecule which 
binds to the target protein at nanomolar concentrations. Using this approach they were 
successful in developing inhibitors against EthR, the transcriptional repressor for 
ethionamide activating protein.115 As development of mutations is a major disincentive for 
anti-TB drug development industry, Prof Blundell also discussed the use of second 
generation sequencing technologies to develop a knowledge-based approach to understand 
evolutionary dynamics. The effects of single nucleotide polymorphisms on protein stability, 
protein-protein/nucleic acid/ligand affinity can now be ascertained by using mCSM, another 
useful web-service tool developed by the group.116  
Identifying drug targets that are druggable is an essential step towards rational drug design. 
The mycobacterial cell wall is unique from Gram-positive and Gram-negative organisms and 
is a good source for anti-mycobacterial drug targets as discussed by Sanjib Bhakta (Birkbeck, 
University of London, UK) and Dirk Schnappinger (Weill Cornell Medical College, USA). It has 
a mycolic acid-arabinogalactan-peptidoglycan complex forming the cell wall core, a 
characteristic feature that has caught the attention of several researchers over the years.  
Disrupting M. tuberculosis’ mycolic acid has proved to be an excellent strategy to target the 
pathogen as illustrated by the success of drugs such as isoniazid, ethambutol and 
pyrazinamide, all of which target mycolic acid synthesis. However, the increasing emergence 
of resistance in M. tuberculosis strains to these drugs has heightened the need for novel 
targets. Biotin is an essential co-factor for all acyl-CoA carboxylases (ACCases), which play a 
role in providing building blocks for the synthesis of the fatty acid component in M. 
tuberculosis cell envelope. Mammalian cells acquire biotin from the external environment 
thus lack these enzymes, therefore validating this pathway for developing intrinsically 
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selective anti-TB drugs.117 Furthermore, mutants in biotin synthesis pathway can cause only 
attenuated forms of infections in mice, suggesting the pathogen is unable to obtain 
exogenous biotin.118 Prof Schnappinger and his group found that mutating one of the 
enzymes, BioA (biotin ligase) in M. tuberculosis made it incapable of surviving in vitro and in 
mice indicating that the de novo biotin synthesis is critical for the pathogen’s survival and 
persistence.119 BioA is susceptible to inhibition, as validated by its inhibition using the 
antibiotic, amiclenomycin.120, 121 However, this antibiotic is too polar and unsuitable for use 
as a part of the lengthy TB treatment regimen. A target-based approached undertaken by 
Prof Schnappinger’s group has identified a potent bisubstrate inhibitor of biotin protein 
ligases (termed as Bio-AMS) from M. tuberculosis which acts by interacting at both the 
biotin and ATP binding pockets.122 This competitive inhibitor was found to be very selective 
and potent against TB strains showing that genetic approaches to facilitate TB drug 
discovery is still worth pursuing.  
Dr Bhakta (Birkbeck, University of London, UK) has pioneered research in the metabolism of 
peptidoglycan (PG) in M. tuberculosis for over a decade.123 The ATP dependent Mur ligase 
genes are involved in the synthesis of PG precursors. These genes are restricted to bacteria 
and have been found essential in mycobacteria by transposon site hybridization (TraSH). The 
structure of murE has been resolved to 3Å and shows an accessible active pocket site that 
can be exploited for drug design.124, 125 Enzymatic inhibition of MurE from M. tuberculosis 
was observed with the extracts from Columbian plants and chemically synthesised 
quinolone compounds thereby demonstrating that the ligases can serve as drug targets.126-
129 Additionally, as cell division and cell wall biogenesis are stringently controlled, co-
operative processes, it is no surprise to find the mur ligase genes clustered in the cell wall 
division (dcw) operon, further indicating that targeting this pathway will have knock-on 
effects on co-regulated pathways.  
The mycobacterial divisome is a multi-factorial complex that assembles at mid-cell and 
brings about cleavage of the bacterial resulting in the formation of two daughter cells. 
Disruption of the cell division process can severely impact the infectivity of the pathogen. 
With this in view, Tim A. Cross (Florida State University, USA) investigated two recruits of 
the divisome, CrgA and ChiZ about whom little is known. The structure of mycobacterial 
CrgA has been modelled with and without the division protein FtsQ. Using solid-state NMR 
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they found CrgA to comprise of two transmembrane helices with very precise rotation axes. 
The exposed glycine residues on the structure are expected to be involved in binding to the 
proteins in the divisome.130 The N–terminus of CrgA is intrinsically disordered, however, Dr 
Cross suggests that in the lipid interface it would probably take up the conformation of a β-
sheet.  
In contrast to expectations, rational drug design has not yielded the number of potential 
lead drug candidates that were obtained from whole-cell phenotypic screening methods 
such as the one discussed by Dr Bhakta. SPOTi is a solid-culture based technique wherein an 
optimised number of bacteria are spotted on to agar containing a series of dilutions of 
inhibitor molecules.131-133 This method has been adapted to 96-well microplate format 
thereby increasing the throughput. 
However, once a potent inhibitor of mycobacterial growth is found it is essential to identify 
the endogenous target of the molecule. There are several available technologies for target 
identification such as genomic-, affinity- and knowledge-based approaches. Cristiano V. 
Bizarro (PUCRS, Brazil) spoke about pulse proteolysis and precipitation for target 
identification (PePTID).134 It is an energetics-based method where protein extracts are 
incubated with or without a ligand followed by the application of a brief proteolytic pulse 
and trichloroacetic acid precipitation. Mass spectrometry is used to analyse the results and 
as a proof-of-concept they applied the methodology to identify ATP-binding proteins using 
non-hydrolysable ATPɣ in M. smegmatis.  
The promising molecules and natural products 
Daniele Castagnolo (King’s College London, UK), Jaroslav Roh (Charles University Prague, 
Czech Republic) and Ill Y. Lee (Korea Research Institute of Chemical Technology, South 
Korea) spoke about promising potential anti-TB specific drugs in different stages of 
development as a result of their research efforts. 
Dr Castagnolo mentioned that using molecules that are similar to candidates that fail in 
clinical trials and optimising them to improve on their characteristics could be a winning 
strategy. He noted that two potent anti-mycobacterial molecules, BM212 and SQ109 have 
similar topological distribution of chemical features. However, they had limitations with 
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respect to pharmacokinetic parameters, solubility, cytotoxicity profile and efficacy against 
MDR M. tuberculosis strains. The group’s strategy was to hybridize the two to generate new 
derivatives to achieve improved anti-TB activity or possibly reduced cytotoxicity. Two 
generations of compounds were synthesised and interestingly the first generation of 
compounds turned out to be potent multidrug efflux pump inhibitors, meaning that these 
molecules could potentiate standard chemotherapy.135 
Dr Lee investigated derivatives such as phenyl ether and carbonate derivatives of 
nitroimidazole as the molecule has space to accommodate reactive groups that could 
improve its anti-mycobacterial profile.136, 137  
Dr Roh investigated 5-substituted 2-[(3,5-dinitrobenzyl)sulfanyl]-1,3,4-oxadiazoles and 1,3,4-
thiadiazoles for their excellent anti-mycobacterial activity against both susceptible and drug 
resistant forms of M. tuberculosis with MIC values as low as 0.03µM. The compounds 
exhibited selective anti-mycobacterial activity with no activity against Gram-positive, Gram-
negative and fungi. There was no cross resistance observed with other first- and second-line 
TB drugs. Structure activity relationship studies demonstrated that 3,5 dinitro phenyl to be 
the crucial fragment conferring anti-mycobacterial activity.138-140 Any changes in position of 
the dinitro group led to the loss or several fold decrease of anti-TB activity. AMES test 
indicated these nitro group-containing compounds have no mutagenic activity.140 They also 
exhibited low cellular toxicity in vitro on three mammalian cell lines. The compounds share 
structural similarities with the inhibitors of DprE1, such as dinitrobenzamides or 
benzothiazinone. However, radiolabeling experiments showed reduction in the 
incorporation of uracil thereby indicating that the bacterial cells suffer from DNA synthesis 
defect on treatment. Further studies on optimization of compounds to improve solubility 
and replacement of the sulfur atom is ongoing as its presence in the molecule makes it 
highly susceptible to metabolic degradation. 
Natural products play an important role in drug discovery and have been a rich source of 
antimicrobials. It is estimated that one-third of the world’s population rely on traditional 
medicine for their healthcare needs. The screening of natural products from higher plants 
constitutes one avenue in the search for new lead antitubercular agents. Maria del Rayo 
Camacho-Corona (Universidad Autónoma de Nuevo León, Mexico) evaluated the anti-
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mycobacterial activity of nine plants used in Mexican traditional medicine. They selected the 
plants based on an extensive search of Mexican ethnobotanical literature.  Some of the 
plants included Citrus sinensis, Citrus aurantifolia, Foeniculum vulgare, Larrea tridentata, 
Musa acuminata and Olea europaea.141 Extracts from various parts of the plants were 
prepared by maceration using hexane, chloroform, methanol and water. The plant extracts 
were tested using the microplate alamar blue assay and tested against M. tuberculosis and 
its MDR isolates. The hexane extract of the fruit peels of Citrus aurantiifolia were 
fractionated by column chromatography and the major compounds were elucidated by 
NMR spectroscopy and GC-MS. Several compounds such as coumarins, linoleic acid, palmitic 
acid and oleic acids were identified, many of which were volatile and found to inhibit the 
growth of the pathogen.  
 
Anti-microbial peptides (AMP) are essential part of innate immunity that helps in combating 
various pathogens. These generally act through disruption of the bacterial cell membranes. 
In aqueous environments, AMPs exists as single molecules. On contact with membranes 
they get ordered and form pores in the membranes. Their action is rapid and effective even 
against highly drug-resistant strains hence have potential to be used as adjunctive 
treatment. Some of them are currently under clinical development for treating several 
bacterial infections. However natural AMPs are not good drug candidates due to their large 
size leading to higher production costs. Drawing inspiration from nature to draw out new 
AMPs, Jasmeet S. Khara (King’s College London, UK) adopted rational design to produce 
peptides with less likelihood to induce resistance and those that demonstrate synergism 
with standard antibiotics.142 There are various strategies to modify AMPs such as 
synthesising peptide conjugates, peptidomimetics and producing hybrid peptides. They 
focussed on de novo design and came up with a primary sequence containing four amino 
acids (xxyy)n  where ‘x’ and ‘y’ are hydrophobic and cationic residues respectively with ‘n’ 
number of repeats. Sequences containing repeating leucine and lysine residues such as 
(LLKK)2 as the backbone with short amphipathic α-helices were found to be anti-
mycobacterial. On addition of methionine residues to the α-helical part, the hydrophobicity 
of the peptide increased which made its insertion into the cell membrane more efficient. 
The peptides exhibited synergism with first line ant-TB drugs and were effective against 
drug-susceptible and drug-resistant strains of M. tuberculosis.  The mechanism of action of 
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these peptides was analysed by scanning electron microscopy and live-cell imaging of 
treated mycobacteria. In the presence of peptides, the membrane of bacterial cells was 
more permeable to dye.  
Drug repositioning: a promising alternative strategy for drug discovery? 
Repurposing has emerged as an attractive strategy to discover drugs that can be directly 
added to the arsenal of drugs used to treat TB infections. Susanne Brighenti (Karolinska 
Institute, Sweden) is interested in enhancing the host’s innate defence system as an 
alternative strategy for the treatment of infectious diseases. A combination of vitamin D3 
and 4-phenylbutyrate (PBA) exhibit a synergistic effect on the production of LL-37 in 
different cell types. LL-37 is an AMP which induces autophagy in M. tuberculosis infected 
human macrophages.143, 144  Increased production of LL-37 could potentially enhance killing 
of both extra-cellular and intra-cellular bacteria as reported earlier. There is no significant 
clinical or microbiological data of the effects of treatment with these drugs. Therefore, 
based on a study carried out in Bangladesh on shigellosis, clinical trial studies were designed 
for execution in Ethiopia and Bangladesh.145 The serum baseline level of vitamin D3 of the 
population in Ethiopia was found to be low and supplementation was recommended. The 
randomised double-blinded clinical trial using daily supplementation of vitamin D and PBA 
as adjunct treatment for standard chemotherapy was conducted to examine the combined 
effects on production of LL-37. Both increased production of LL-37 in human macrophages 
and LL-37 dependent autophagy in infected macrophages. They also observed reduced 
clinical symptoms with enhanced recovery and rapid sputum culture conversion on adjunct 
therapy with vitD3 alone or in combination with PBA. Therefore, vitD3 and PBA can 
counteract down regulation of LL-37 during infection which can have positive impact on 
reducing antibiotic requirements for cure.145-147 
Dr Bhakta’s group reported the common, over-the-counter non-steroidal anti-inflammatory 
drugs (NSAIDs), ibuprofen and carprofen to be anti-tubercular.131, 148, 149 They were found to 
be active against drug resistant strains and stationary phase mycobacteria. The endogenous 
mechanism of action of these drugs is still under debate, however, transcriptomic analyses 
reveal that the drugs may have pleiotropic effects on the pathogen. Additionally, the 
immunomodulatory effects of NSAIDs and the protection it offers from tissue inflammation 
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and damage is the leading argument to include this class of drugs as host-directed adjunct 
therapies to complement the standard anti-TB treatment in an effort to improve treatment 
outcomes.  
M. tuberculosis possess a two-regulatory system PhoPR, that is important in sensing and 
responding to the acidic environment found in macrophages and using it to its own 
advantage. Robert Abramovitch (Michigan State University, USA) strived to find a 
compound that inhibits the regulatory system making the pathogen susceptible to the host’s 
immune responses. Whole-cell phenotypic screens were employed to identify inhibitors of 
the regulon. High-throughput screens of nearly 220,000 compound libraries identified 
ethoxzolamide to inhibit the regulon while having no effect on the growth of the pathogen. 
Ethoxzolamide is a carbonic anhydrase inhibitor which is used to treat glaucoma and 
duodenal ulcers. Transcriptional studies show ethoxzolamide to down-regulate 45 genes in 
M. tuberculosis. These genes are known to control lipid synthesis, carbon metabolism and 
virulence. As a main finding of this study, they state that ethoxzolamide does not change M. 
tuberculosis’ pH homeostasis but inhibits its pH-dependent adaption and virulence.150  
Gerry Davies (University of Liverpool, UK) revealed that the problem with development of 
new treatment is the lack of integrated approach in pharmacokinetic and pharmacodynamic 
analyses of clinical outcomes, together with poorly designed animal studies leading to 
failures in clinical trials. This is an exciting time for the field clinical development of drugs for 
TB as several new and repurposed drugs are under trial. Phase II B trials of one of the few 
promising candidates, the fluoroquinolones gatifloxacin and moxifloxacin, suggested that 
the drugs were working well and accelerating the rate of culture conversion in early clinical 
development giving hope for shortening therapy and reducing relapse rates. Phase III trials, 
where moxifloxacin was incorporated into first line drug regimens as a mean of shortening 
treatment down to 4 months were carried out ended up to be a disappointment. Dr Davies 
suggests a seamless trial design concept with a core outcome set.  This would enable 
outcomes are to be assessed at several intermediate points and the arms that perform 
poorly, discontinued. Hence resources and patients can be channelled to the arms that 
perform well at carefully selected junctures to minimise losses of funds and time.151 
Conclusion  
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There is significant evidence to support the fact that developing cheap and reliable 
diagnostics would be pivotal in the control this disease. Diagnostic tests with low 
turnaround times will reduce the number of patients lost to treatment; additionally, those 
that can profile drug susceptibility will improve treatment outcomes. Lateral flow assays and 
molecular diagnostics offer a lot of hope in this regard. Their initial successes will hopefully 
garner interest and funding for improving on the respective technologies.  
Early and accurate detection of the disease can only be an effective means of control if an 
arsenal of robust, effective drugs against a spectrum of resistance phenotypes exists. To 
overcome hurdles of developing novel chemical entities from scratch, researchers are now 
making informed decisions and focussing their efforts in alternative approaches including 
strategies such as repositioning drugs, host-directed therapy and improving on previously 
unsuccessful drug candidates. These strategies have now populated the clinical trials 
pipeline with more molecules and possibilities than seen since the golden age of antibiotic 
discovery.  
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